Phase II study of sunitinib in men with advanced prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of sunitinib in men with advanced prostate cancer

Published:2009-05 Issue:5 Volume:20 Page:913-920
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Dror Michaelson M.,Regan M.M.,Oh W.K.,Kaufman D.S.,Olivier K.,Michaelson S.Z.,Spicer B.,Gurski C.,Kantoff P.W.,Smith M.R.

Funder

Department of Defense Prostate Cancer Research Program Clinical Trial Award number

NIH K24 Midcareer Investigator Award

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/5/913/354554/mdp111.pdf

Reference30 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor;Singh;Clin Cancer Res,2004

5. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics;Takei;Cancer Res,2004

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From the Drugbank Application to the Novel Drugs: A Pharmacogenomic Summary;E3S Web of Conferences;2024

2. Resistance of prostate cancer to kinase inhibitors;Therapy Resistance in Prostate Cancer;2024

3. Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies;International Journal of Molecular Sciences;2023-10-31

4. Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions;BioChem;2023-08-29

5. Computational design of DNA binding domain-retained fusion proteins and virtual screening against FDA-approved drugs;2023-05-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3